Revenue and Financial Performance - The company has not generated any revenue from drug sales to date, relying primarily on milestone payments and collaboration agreements[87]. - Revenue for the nine months ended September 30, 2024, included a $1.0 million increase due to the Newsoara License Agreement, while there was no revenue in the same period of 2023[102]. - The net loss attributable to vTv Therapeutics Inc. for Q3 2024 was $4.8 million, a decrease of $1.9 million compared to a net loss of $6.7 million in Q3 2023[95]. - Net cash used in operating activities increased to $20.5 million for the nine months ended September 30, 2024, compared to $16.2 million in 2023[111]. - Net cash provided by financing activities was $52.6 million for the nine months ended September 30, 2024, significantly up from $12.3 million in 2023[111]. - As of September 30, 2024, the company had cash and cash equivalents of $41.6 million and an accumulated deficit of $296.1 million[108]. Research and Development - Research and development expenses for Q3 2024 were $3.2 million, an increase of $0.4 million or 14.2% compared to $2.8 million in Q3 2023[97]. - Research and development expenses for cadisegliatin were $1.5 million in Q3 2024, down from $1.9 million in Q3 2023[89]. - Research and development expenses decreased by $2.1 million, or 18.7%, to $9.3 million for the nine months ended September 30, 2024, from $11.5 million in 2023[103]. - The lead program, cadisegliatin, received FDA Breakthrough Therapy designation in 2021, supported by positive Phase 2 trial results showing a 40% reduction in severe hypoglycemia[84]. - The FDA placed a clinical hold on the cadisegliatin program on July 26, 2024, requiring further study before resuming trials[84]. - The company plans to initiate two international registrational studies for cadisegliatin in type 1 diabetes, expected to start in 2026[84]. - The company is collaborating with G42 to initiate a Phase 2 trial in the Middle East for type 2 diabetes, anticipated to begin in 2025[85]. Operating Expenses - Total operating expenses for Q3 2024 were $6.5 million, up from $5.4 million in Q3 2023, reflecting an increase of $1.1 million[95]. - General and administrative expenses increased by $1.6 million, or 17.5%, to $11.0 million for the nine months ended September 30, 2024, compared to $9.3 million in 2023[104]. Financing and Capital Requirements - The company closed a private placement financing of up to $51.0 million on February 27, 2024, to advance its lead program for cadisegliatin[108]. - The company entered into a sales agreement with TD Cowen to offer up to $50.0 million of Class A common stock, with $2.5 million already raised[109]. - The company anticipates needing substantial additional funding to continue operations and clinical trials, with future capital requirements dependent on various factors including regulatory approvals and clinical trial progress[113]. Market and Investment Risks - The company does not currently have any material interest rate exposure[120]. - The exposure to market risk is limited to cash and cash equivalents, all with maturities of one year or less[121]. - The investment strategy focuses on capital preservation, liquidity needs, and fiduciary control of cash and investments[121]. - The company seeks to maximize income from investments without assuming significant risk[121]. - There is no material foreign currency exposure reported[122].

Financial Performance - Net loss attributable to vTv shareholders for Q3 2024 was $4.8 million, or $0.88 per basic share, an improvement from a net loss of $6.7 million, or $3.19 per basic share, in Q3 2023[2][4] - The company reported an operating loss of $6.5 million for Q3 2024, compared to an operating loss of $5.4 million in Q3 2023[4] - Other income for Q3 2024 was $0.2 million, compared to an expense of $3.3 million in Q3 2023, indicating a significant turnaround[2] Cash and Assets - Cash position increased to $41.6 million as of September 30, 2024, up from $9.4 million as of December 31, 2023[2] - Total current assets increased to $42.96 million as of September 30, 2024, compared to $10.66 million as of December 31, 2023[3] - Total liabilities decreased to $25.25 million as of September 30, 2024, down from $29.57 million as of December 31, 2023[3] Expenses - Research and Development (R&D) expenses for Q3 2024 were $3.2 million, compared to $2.8 million in Q3 2023, reflecting a 14.3% increase[2] - General and Administrative (G&A) expenses rose to $3.3 million in Q3 2024 from $2.5 million in Q3 2023, marking a 32% increase[2] Product Development - The company is progressing with the cadisegliatin program, aimed at improving glycemic control in type 1 diabetes patients, and is in discussions with the FDA regarding a clinical hold[1] - vTv Therapeutics is focused on developing oral, small molecule drug candidates, with cadisegliatin as a lead program for type 1 diabetes[5]

Financial Position - vTv Therapeutics reported a cash position of $45.5 million as of June 30, 2024, up from $9.4 million at the end of 2023, attributed to private placement financing[4] - The net loss attributable to vTv shareholders for Q2 2024 was $5.2 million, or $0.81 per share, compared to a net loss of $5.6 million, or $2.69 per share, in the same period last year[6] - Total operating expenses for Q2 2024 were $7.2 million, down from $8.0 million in Q2 2023, indicating a decrease of approximately 10%[9] Research and Development - Research and Development (R&D) expenses decreased to $3.4 million in Q2 2024 from $4.7 million in Q2 2023, a reduction of approximately 28%[4] - The first patient was screened in the pivotal trial for cadisegliatin for type 1 diabetes (T1D), although the FDA placed a clinical hold on the program due to unresolved issues in a recent study[2] - vTv Therapeutics has dosed over 500 subjects in cadisegliatin studies, including 300 patients with type 1 and type 2 diabetes, demonstrating its potential for improved glycemic control[1] - The company is actively working with the FDA to resolve the clinical hold on cadisegliatin and aims to resume the study as soon as possible[2] General and Administrative Expenses - General and Administrative (G&A) expenses increased to $3.7 million in Q2 2024 from $3.3 million in Q2 2023, reflecting a rise of about 12%[5] Licensing and Designation - vTv Therapeutics expanded its licensing agreement with Newsoara Biopharma for the PDE4 inhibitor HPP737 to a global license, contingent upon a $20 million upfront fee and potential milestones totaling up to $76 million[2] - Azeliragon received Orphan Drug Designation from the FDA for pancreatic cancer and glioblastoma, with potential revenue sharing of 20-40% from licensing income[3]

Regulatory Updates - The FDA placed a clinical hold on the cadisegliatin clinical program, including the ongoing CATT1 Phase 3 trial for type 1 diabetes, due to unresolved chromatographic signals in a recent study[76]. - Cadisegliatin received Breakthrough Therapy designation from the FDA in 2021, supported by positive results from the Phase 2 SimpliciT-1 Study, which showed a 40% reduction in severe hypoglycemia[79]. Financial Performance - The company reported no revenue for the three months ended June 30, 2024, consistent with the same period in 2023[90]. - Revenue for the six months ended June 30, 2024, was $1.0 million, an increase due to the satisfaction of a development milestone under the Newsoara License Agreement[96]. - The net loss attributable to vTv Therapeutics Inc. for Q2 2024 was $5.2 million, a decrease of $0.4 million from a net loss of $5.6 million in Q2 2023[89]. - Total operating expenses for Q2 2024 were $7.2 million, a decrease of $0.8 million from $8.0 million in Q2 2023[89]. - Net cash used in operating activities increased to $(14.1) million for the six months ended June 30, 2024, compared to $(11.3) million in 2023[105]. - Net cash provided by financing activities was $50.1 million for the six months ended June 30, 2024, significantly higher than $11.8 million in 2023[104]. - As of June 30, 2024, the company had cash and cash equivalents of $45.5 million and an accumulated deficit of $291.3 million[102]. - The company has not generated any revenue from drug product sales and does not expect to until regulatory approval is obtained[106]. Research and Development - Research and development expenses for Q2 2024 were $3.4 million, a decrease of $1.3 million or 26.7% compared to $4.7 million in Q2 2023, primarily due to lower spending on cadisegliatin[91]. - Research and development expenses decreased by $2.5 million, or 29.5%, to $6.1 million for the six months ended June 30, 2024, primarily due to lower spending on cadisegliatin[97]. - The company plans to initiate two international registrational studies for cadisegliatin in type 1 diabetes, expected to start in 2026[79]. - The company continues to work with G42 Investments to initiate a Phase 2 trial in the Middle East for type 2 diabetes, expected to begin in 2024[79]. Administrative Expenses - General and administrative expenses increased to $3.7 million in Q2 2024, up $0.4 million or 12.3% from $3.3 million in Q2 2023, driven by higher share-based expenses and legal costs[92]. - General and administrative expenses increased by $0.9 million, or 13.2%, to $7.7 million for the six months ended June 30, 2024, driven by higher payroll and legal expenses[98]. Interest Income - Interest income for Q2 2024 was $0.6 million, compared to $0.2 million in Q2 2023, primarily from dividends and interest from money market accounts[93]. - Interest income for the six months ended June 30, 2024, was $0.6 million, up from $0.3 million in the same period of 2023[99]. Financial Strategy and Risk Management - The company anticipates needing substantial additional funding to continue operations and clinical trials[106]. - The company closed a private placement financing of up to $51.0 million on February 27, 2024, to advance its lead program for cadisegliatin[102]. - The company has no material interest rate exposure, indicating a stable financial position regarding interest rates[111]. - The exposure to market risk is limited to cash and cash equivalents, all with maturities of one year or less[112]. - The investment strategy focuses on capital preservation, liquidity fulfillment, and fiduciary control of cash and investments[112]. - The company aims to maximize income from investments without assuming significant risk[112]. - There is no material foreign currency exposure, suggesting minimal risk from currency fluctuations[113].

Core Insights - vTv Therapeutics Inc. has initiated a pivotal trial for cadisegliatin, a potential first-in-class oral therapy for type 1 diabetes (T1D), while addressing a clinical hold imposed by the FDA [1][3][4] - The company has expanded its licensing agreement with Newsoara Biopharma for the PDE4 inhibitor HPP737 to a global license, contingent upon a $20 million upfront fee [1][3] - Financial results for Q2 2024 show a net loss of $5.2 million, a slight improvement from a net loss of $5.6 million in the same period last year [4][10] Company Developments - The first patient has been screened in the cadisegliatin pivotal trial for T1D, which is part of a series of trials aimed at regulatory submission [3] - The FDA placed a clinical hold on the cadisegliatin program due to unresolved chromatographic signals in a recent study, requiring an additional in vitro study before resuming [3][4] - Cadisegliatin has previously received Breakthrough Therapy designation from the FDA, indicating its potential to improve glycemic control and reduce hypoglycemia in diabetes patients [3] Financial Performance - As of June 30, 2024, the company's cash position increased to $45.5 million from $9.4 million at the end of 2023, primarily due to private placement financing [4] - Research and Development (R&D) expenses decreased to $3.4 million in Q2 2024 from $4.7 million in Q2 2023, attributed to lower spending on cadisegliatin [4][5] - General and Administrative (G&A) expenses rose to $3.7 million in Q2 2024 from $3.3 million in Q2 2023, driven by increased share-based expenses and legal costs [5][10] Licensing and Partnerships - The amended global licensing agreement for HPP737 includes potential development milestones of up to $41 million and sales-related milestones of up to $35 million, along with mid to upper single-digit royalties [3] - Azeliragon, a partnered program with Cantex Pharmaceuticals, received Orphan Drug Designation for pancreatic cancer and is advancing in multiple clinical trials [2][3]

Core Points - VTv Therapeutics' stock is experiencing a significant decline due to the FDA placing a clinical hold on its cadisegliatin clinical program, which includes the TT1 Phase 3 trial for type 1 diabetes [1][4] - The clinical hold requires the company to conduct an in vitro study to characterize a chromatographic signal observed in a human absorption, distribution, metabolism, and excretion (ADME) study [2][3] - As a result of the news, VTv Therapeutics' stock is down 45.7% as of Monday morning, with trading volume exceeding 10,000 shares, slightly below the daily average of approximately 15,000 shares [3][4] Company Response - VTv Therapeutics' chairman, president, and CEO, Paul Sekhri, emphasized that patient safety is the company's top priority and expressed appreciation for the FDA's thoroughness in understanding the signal [2][3] - The company is actively working with the FDA to resolve the clinical hold and aims to resume enrollment in the trial as quickly as possible [3]

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolera ...

The clinical hold was based on the discovery of a chromatographic signal in a recent human absorption, distribution, metabolism, and excretion (ADME) study of cadisegliatin that could not be resolved by standard mass spectroscopy. The Agency requires a single in vitro study to characterize this signal before the cadisegliatin program can resume. No patient had been dosed in CATT1 at the time of the clinical hold, and past clinical studies did not reveal any clinically concerning safety issues. Cadisegliatin ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________ FORM 10-Q _____________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37524 _____________________________ vTv Therapeuti ...

Exhibit 99.1 vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate Update HIGH POINT, N.C. – May 9, 2024 – vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments. "The first quarter of 2024 saw us reach several ...